Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Autor: | Sangana R; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Xu Y; Genentech Research and Early Development, South San Francisco, CA, USA., Shah B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Tian X; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Zack J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Shakeri-Nejad K; Novartis Pharma AG, Basel, Switzerland., Kalluri S; Novartis Healthcare Pvt, Hyderabad, India., Jones I; Novartis Pharma AG, Basel, Switzerland., Ligueros-Saylan M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Taylor AF; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Jain DK; Novartis Pharma AG, Basel, Switzerland., Scosyrev E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Uddin A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Laurent N; Novartis Pharma AG, Basel, Switzerland., Paganoni P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Jun; Vol. 13 (6), pp. 611-620. Date of Electronic Publication: 2024 Feb 22. |
DOI: | 10.1002/cpdd.1373 |
Abstrakt: | Omalizumab is an anti-IgE monoclonal antibody currently approved for the treatment of asthma, nasal polyps/chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Omalizumab is available as an injection in a prefilled syringe (PFS) with a needle safety device (NSD). New product configurations were developed to reduce the number of injections per dose administration, improve patient convenience and treatment compliance. The objective of this randomized open-label 12-week study was to demonstrate pharmacokinetic bioequivalence between (1) new PFS with autoinjector (PFS-AI), (2) new PFS-NSD configuration, and (3) current PFS-NSD configuration. Each new configuration was considered bioequivalent to the current configuration if the confidence intervals (CIs) for the geometric mean ratios (GMR) were contained in the 0.80-1.25 range for maximum concentration (C (© 2024 Novartis Pharmaceuticals. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.) |
Databáze: | MEDLINE |
Externí odkaz: |